Cargando…

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST

Background: We aimed to examine the feasibility and potential benefit of applying PET Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast cancer (MBC). Further, we introduced the nadir scan as a reference. Methods: Response monitoring FDG-PET/CT scans in 37 women...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogsen, Marianne, Bülow, Jakob Lykke, Ljungstrøm, Lasse, Oltmann, Hjalte Rasmus, Alamdari, Tural Asgharzadeh, Naghavi-Behzad, Mohammad, Braad, Poul-Erik, Gerke, Oke, Hildebrandt, Malene Grubbe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073831/ https://www.ncbi.nlm.nih.gov/pubmed/33921580 http://dx.doi.org/10.3390/diagnostics11040723

Ejemplares similares

Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2021)

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020)

Prognostic Value of Dual-Time-Point (18)F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2020)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
por: Hildebrandt, Malene Grubbe, et al.
Publicado: (2019)

Comparison of Image Quality and Quantification Parameters between Q.Clear and OSEM Reconstruction Methods on FDG-PET/CT Images in Patients with Metastatic Breast Cancer
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2023)

FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review
por: Helland, Fredrik, et al.
Publicado: (2019)

Cost-effectiveness of 2-[(18)F]FDG-PET/CT versus CE-CT for response monitoring in patients with metastatic breast cancer: a register-based comparative study
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2023)

2-[(18)F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer
por: Vogsen, Marianne, et al.
Publicado: (2023)

Benefits and harms of implementing [(18)F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study
por: Vogsen, Marianne, et al.
Publicado: (2021)

The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [(18)F]FDG-PET/CT and CE-CT
por: Gram-Nielsen, Rosa, et al.
Publicado: (2023)

Prevalence of focal incidental breast uptake on FDG-PET/CT and risk of malignancy: a systematic review and meta-analysis
por: Aarstad, Else Marie, et al.
Publicado: (2019)

Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
por: Hansen, Jeanette Ansholm, et al.
Publicado: (2021)

Learning from patient involvement in a clinical study analyzing PET/CT in women with advanced breast cancer
por: Vogsen, Marianne, et al.
Publicado: (2020)

Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
por: Holm, Jorun, et al.
Publicado: (2020)

Perspective of Patients With Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed Methods Study
por: Baun, Christina, et al.
Publicado: (2020)

Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study
por: Gerke, Oke, et al.
Publicado: (2017)

2-[18F]FDG-PET/CT in Cancer of Unknown Primary Tumor—A Retrospective Register-Based Cohort Study
por: Rimer, Heidi, et al.
Publicado: (2023)

Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
por: Baun, Christina, et al.
Publicado: (2018)

Low-Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care
por: Høilund-Carlsen, Poul Flemming, et al.
Publicado: (2020)

Value assessment of artificial intelligence in medical imaging: a scoping review
por: Fasterholdt, Iben, et al.
Publicado: (2022)

Correction: Value assessment of artificial intelligence in medical imaging: a scoping review
por: Fasterholdt, Iben, et al.
Publicado: (2023)

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022)

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership
por: Hildebrandt, Malene Grubbe, et al.
Publicado: (2022)

(18)F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis
por: Burglin, Synne Alexandra, et al.
Publicado: (2017)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

A randomised trial of [(18)F]PSMA‐1007‐PET/CT versus NaF‐PET/CT for staging primary prostate cancer: A trial protocol
por: Buch‐Olsen, Karen Middelbo, et al.
Publicado: (2023)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

Quantitation of cancer treatment response by 2-[(18)F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
por: O, Joo Hyun, et al.
Publicado: (2021)

A prospective study on dual time (18)F-FDG-PET/CT in high-risk prostate cancer patients
por: Mortensen, Mike Allan, et al.
Publicado: (2018)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

Factors That Affect PERCIST-Defined Test-Retest Comparability: An Exploration of Feasibility in Routine Clinical Practice
por: Yuan, Hui, et al.
Publicado: (2015)

Role of FDG-PET/CT in Assessing the Correlation Between Blood Pressure and Myocardial Metabolic Uptake
por: Rojulpote, Chaitanya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8pjnvqn5j98ch4crl45691d0n